Evans Blue Dye Derivatives for Serum Albumin Labeling

The invention is an imaging agent and method of use for imaging blood pools and the lymphatic system. The imaging agent binds with high affinity to serum albumin, the most abundant serum protein, and can be tagged with several isotopes making it suitable for magnetic resonance imaging or positron emission tomographic imaging. To date, only very few blood-pool tracers have been introduced for positron emission tomography. The existing ones have short half-lives (20.4 min for 11C and 2.05 min for 15O) and thus can only be used in centers with an in-house cyclotron. Compared with these radiometals, 18F has the advantages of being a pure position emitter with ideal half-life. It is the dominant radioisotope used for PET imaging for both clinical applications and preclinical investigations. Evans blue dye has been an important tool in many physiological and clinical investigations because of its high affinity for plasma albumin and has been used for a long time in clinical practice for determination of patient plasma volume. By taking advantage of the high in-vivo EB binding affinity to albumin, the current imaging agent is a NOTA conjugate of truncated form of Evans blue (NEB) for in vivo albumin labeling and then labeling with 18F labeling by the formation of 18F-aluminum fluoride complex. The NOTA also facilitates radiometal labeling of NEB with either 68Ga or 64Cu. The resulting imaging agent does not affect the in vivo behavior of serum albumin such as circulation, extra-vascularization, and turn-over; thus the imaging results will reflect the distribution and metabolism of serum albumin accurately.

Potential Commercial Applications: Competitive Advantages:
  • Blood pool imaging
  • Lymphatic system imaging


Xiaoyuan Chen (NIBIB)  ➽ more inventions...

Lixin Lang (NIBIB)  ➽ more inventions...

Gang NIU (NIBIB)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 10258701 issued 2019-04-16
US Application No. 14/675,364

Collaboration Opportunity:

The National Institute of Biomedical Imaging and Bioengineering seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate this technology. Please contact Cecilia Pazman, Office of Technology Transfer, National Heart, Lung and Blood Institute; pazmance@nhlbi.nih.gov; 301-594-4273.

Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-099-2015-0
Updated: Aug 24, 2017